骨髓增殖性肿瘤中的血栓形成：使用全血血小板聚集研究进行风险评估和血栓预防的单中心经验。
Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis.
机构信息
Southern Sydney Haematology, St George Private Hosipital, Sydney, Australia.
Faculty of Health, Medicine & Applied Sciences, 8691University of Wollongong, Wollongong, New South Wales, Australia.
出版信息
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221117482. doi: 10.1177/10760296221117482.
Abstract
Routine use of WBPA studies enables safe and effective risk-adapted thromboprophylaxis in MPN patients, irrespective of the underlying driver mutation and their risk predicted by the IPSET- thrombosis criteria.
摘要
常规应用 WBPA 研究可使 MPN 患者安全有效地进行风险适应性抗血栓治疗，无论其潜在的驱动突变以及基于 IPSET-thrombosis 标准预测的风险如何。
相似文献
1
Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221117482. doi: 10.1177/10760296221117482.
2
Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
Thromb Res. 2016 Apr;140 Suppl 1:S71-5. doi: 10.1016/S0049-3848(16)30102-5.
3
How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
Hamostaseologie. 2020 Feb;40(1):47-53. doi: 10.1055/s-0040-1701474. Epub 2020 Feb 12.
4
Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
Semin Thromb Hemost. 2019 Sep;45(6):604-611. doi: 10.1055/s-0039-1693477. Epub 2019 Aug 5.
5
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
Ann Hematol. 2014 Dec;93(12):1953-63. doi: 10.1007/s00277-014-2224-8. Epub 2014 Oct 14.
6
Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.
Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e425-e429. doi: 10.1016/j.clml.2019.05.005. Epub 2019 May 13.
7
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Acta Haematol. 2013;130(3):181-7. doi: 10.1159/000348413. Epub 2013 Jun 8.
8
Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms.
Platelets. 2018 Nov;29(7):723-728. doi: 10.1080/09537104.2017.1361018. Epub 2017 Nov 1.
9
Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.
Postgrad Med. 2021 Jun;133(5):508-516. doi: 10.1080/00325481.2021.1880844. Epub 2021 Feb 9.
10
Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group.
Acta Haematol. 2021;144(4):438-445. doi: 10.1159/000511426. Epub 2020 Dec 14.
引用本文的文献
1
Management of Bleeding, Thrombotic and Pregnancy-Related Complications in Women with Myeloproliferative Neoplasms: A Case-Based Review Focusing on Sex-Specific Challenges.
J Clin Med. 2025 Feb 25;14(5):1537. doi: 10.3390/jcm14051537.
2
Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera.
J Clin Med. 2024 Aug 22;13(16):4952. doi: 10.3390/jcm13164952.
3
A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery.
Cureus. 2024 Mar 12;16(3):e56008. doi: 10.7759/cureus.56008. eCollection 2024 Mar.
4
Incidence of Thrombosis at Different Sites During the Follow-Up Period in Essential Thrombocythemia: A Systematic Review and Meta-Analysis.
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231181117. doi: 10.1177/10760296231181117.
本文引用的文献
1
Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.
Eur J Haematol. 2022 Feb;108(2):154-162. doi: 10.1111/ejh.13721. Epub 2021 Nov 10.
2
Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Eur J Haematol. 2021 Dec;107(6):624-633. doi: 10.1111/ejh.13700. Epub 2021 Sep 30.
3
The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.
Blood. 2021 Apr 22;137(16):2152-2160. doi: 10.1182/blood.2020008109.
4
Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.
Blood. 2021 Mar 4;137(9):1145-1153. doi: 10.1182/blood.2020008043.
5
Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia.
Front Immunol. 2020 Apr 30;11:705. doi: 10.3389/fimmu.2020.00705. eCollection 2020.
6
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.
Blood. 2020 Jul 9;136(2):171-182. doi: 10.1182/blood.2019004596.
7
Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.
Am J Hematol. 2020 Apr;95(4):379-386. doi: 10.1002/ajh.25713. Epub 2020 Jan 8.
8
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation.
Cells. 2019 Aug 8;8(8):854. doi: 10.3390/cells8080854.
9
Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Cancer Treat Res. 2019;179:159-178. doi: 10.1007/978-3-030-20315-3_11.
10
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.
Ann Intern Med. 2018 Mar 6;168(5):317-325. doi: 10.7326/M17-0028. Epub 2018 Jan 16.
Zotero 插件